BioSpace News Archive

1,000 COVID-19 test kits will be distributed each week to Federally Qualified Health Centers in Georgia

Luminex Corporation (NASDAQ: LMNX) (“Luminex”) announced today the pricing of its offering of $260,000,000 aggregate principal amount of 3.00% Convertible Senior Notes due 2025 (the “Convertible Notes”) in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The delivery of th

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that management will present at two upcoming investor conferences:

Presented Interim Clinical Data for OTX-TKI Showing Favorable Safety Profile, Tolerability, Durability and Early Biological Activity Announced Positive Phase 3 Clinical Trial for DEXTENZA in Allergic Conjunctivitis; Plan to File sNDA with the U.S. Food and Drug Administration by the End of 2020 First Quarter DEXTENZA® Net Product Revenue of $2.1 million, a 31% Sequential Increase Compared with Fourth Quarter of 2019

The Annual General Meeting of Immunovia AB, corporate identity number 556730-4299 was held in The Spark at Medicon Village, Scheeletorget 1, Lund on May 7, 2020.

SAN FRANCISCO, May 08, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the company’s Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2020 Virtual Global Healthcare Conference on Thursday May 14, 2020 at 11:00 AM ET and the RBC Capital Markets 2020

Oncogenuity, Inc., a Fortress partner company, enters into an agreement with Columbia University to develop a broad platform technology using oligonucleotides Initial target is KRAS-driven cancers, often considered “un-druggable” Platform being explored as a treatment for coronaviruses, including COVID-19 NEW YORK, May 08, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company, today announced that Oncogenuity, Inc. (“Oncog

Cynata Therapeutics Limited (ASX: “ CYP”, “Cynata”, or the “Company” ), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that it has received ethics committee approval to commence a clinical trial to investigate early efficacy of Cynata’s proprietary Cymerus™ mesenchymal stem cells (MSCs) in adults admitted to intensive care with COVID-19. In addition, the Company also provides updated gui

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that President Rajiv Malik and Chief Financial Officer Ken Parks will present at the BofA Securities Virtual Health Care Conference 2020 on Thursday, May 14, 2020 at 3:40 p.m. ET.

American Renal Associates Holdings, Inc., a leading kidney care and dialysis provider focused on partnering with local nephrologists, announced that Christopher J. Hocevar has been appointed to join the Company’s board of directors and that Steve M. Silver, who has served on ARA’s board for a number of years, has transitioned his board seat to Jeremy W. Gelber, M.D.